Predictive biomarkers of chemotherapy-induced peripheral neuropathy: a review-Reference-Cited by-同舟云学术

Predictive biomarkers of chemotherapy-induced peripheral neuropathy: a review

Published:2018-08 Issue:8 Volume:12 Page:907-916
ISSN:1752-0363
Container-title:Biomarkers in Medicine
language:en
Short-container-title:Biomarkers in Medicine

Author:

Diaz Patrick L¹,Furfari Anthony¹,Wan Bo Angela¹,Lam Henry¹,Charames George²³⁴⁵,Drost Leah¹,Fefekos Angelo⁶,Ohearn Shannon⁶,Blake Alexia⁶,Asthana Rashi¹,Chow Edward¹,DeAngelis Carlo¹⁷

Affiliation:

1. Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, M4N 3M5, Canada

2. Pathology & Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, M5G 1X5, Canada

3. Laboratory Medicine & Pathobiology, University of Toronto, Toronto, Ontario, M5S 1A8, Canada

4. Mount Sinai Services Inc., Toronto, Ontario, M5G 1X5, Canada

5. Lunenfeld–Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, M5G 1X5, Canada

6. MedReleaf Inc., Markham, Ontario, L3R 6G4, Canada

7. Department of Pharmacy, Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, M4N 3M5, Canada

Abstract

Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of taxane treatment during chemotherapy. Identifying predictive biomarkers of CIPN would allow physicians to alter treatment given to patients according to a personal risk of developing this condition. The current literature on CIPN biomarkers is reviewed, identifying biomarkers which have been found to be significantly related to CIPN. Three genetic biomarkers are identified (ARHGEF10 rs9657362, CYP2C8 rs11572080/rs10509681 and FGD4 rs10771973) which have been found to act as predictive CIPN biomarkers in multiple studies. Possible mechanisms underlying the relationship between these single nucleotide polymorphisms and CIPN development are explored. The biomarkers identified in this study should be investigated further to generate predictive biomarkers that may be used in a clinical setting.

Publisher

Future Medicine Ltd

Subject

Biochemistry (medical),Clinical Biochemistry,Drug Discovery

Link

https://www.futuremedicine.com/doi/pdf/10.2217/bmm-2017-0427

Reference58 articles.

1. Cellular and clinical pharmacology of the taxanes docetaxel and paclitaxel – a review

2. Pharmacogenetics of taxanes: impact of gene polymorphisms of drug transporters on pharmacokinetics and toxicity

3. Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy

4. Chemotherapy-induced peripheral neurotoxicity (CIPN): An update

5. Deconstructing the Neuropathic Pain Phenotype to Reveal Neural Mechanisms

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Machine learning and biological validation identify sphingolipids as potential mediators of paclitaxel-induced neuropathy in cancer patients;2024-08-22

2. Machine learning and biological validation identify sphingolipids as potential mediators of paclitaxel-induced neuropathy in cancer patients;2024-08-22

3. Machine learning and biological validation identify sphingolipids as key mediators of paclitaxel-induced neuropathy in cancer patients;2024-03-19

4. Machine learning and biological validation identify sphingolipids as key mediators of paclitaxel-induced neuropathy in cancer patients;2023-10-09

5. Genetic polymorphism of pleiotrophin is associated with pain experience in Japanese adults: Case-control study;Medicine;2022-09-16